BACKGROUND: Apnea of prematurity (AOP) is a common complication of preterm birth, for which caffeine is the first treatment of choice. In case of persistent AOP, doxapram has been advocated as an additional therapy. OBJECTIVE: To identify and appraise all existing evidence regarding efficacy and safety of doxapram use for AOP in infants born before 34 weeks of gestational age. METHODS: All studies reporting on doxapram use for AOP were identified by searching electronic databases, references from relevant studies, and abstracts from the Societies for Pediatric Research. Two reviewers independently assessed study eligibility and quality, and extracted data on study design, patient characteristics, efficacy and safety outcomes. RESULTS: The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline. No serious adverse effects were reported. We identified 28 observational studies consisting mainly of cohort studies and case series (n = 1,994). There was considerable heterogeneity in study design and quality. Most studies reported a positive effect of doxapram on apnea rate. A few studies reported on long-term outcomes with conflicting results. A range of possible doxapram-related short-term adverse effects were reported, sometimes associated with the use of higher doses. CONCLUSION: Based on the limited number of studies and level of evidence, no firm conclusions on the efficacy and safety of doxapram in preterm infants can be drawn. For this reason, routine use cannot be recommended. A large multicenter randomized controlled trial is urgently needed to provide more conclusive evidence.
BACKGROUND:Apnea of prematurity (AOP) is a common complication of preterm birth, for which caffeine is the first treatment of choice. In case of persistent AOP, doxapram has been advocated as an additional therapy. OBJECTIVE: To identify and appraise all existing evidence regarding efficacy and safety of doxapram use for AOP in infants born before 34 weeks of gestational age. METHODS: All studies reporting on doxapram use for AOP were identified by searching electronic databases, references from relevant studies, and abstracts from the Societies for Pediatric Research. Two reviewers independently assessed study eligibility and quality, and extracted data on study design, patient characteristics, efficacy and safety outcomes. RESULTS: The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline. No serious adverse effects were reported. We identified 28 observational studies consisting mainly of cohort studies and case series (n = 1,994). There was considerable heterogeneity in study design and quality. Most studies reported a positive effect of doxapram on apnea rate. A few studies reported on long-term outcomes with conflicting results. A range of possible doxapram-related short-term adverse effects were reported, sometimes associated with the use of higher doses. CONCLUSION: Based on the limited number of studies and level of evidence, no firm conclusions on the efficacy and safety of doxapram in preterm infants can be drawn. For this reason, routine use cannot be recommended. A large multicenter randomized controlled trial is urgently needed to provide more conclusive evidence.
Authors: Peter G Davis; Barbara Schmidt; Robin S Roberts; Lex W Doyle; Elizabeth Asztalos; Ross Haslam; Sunil Sinha; Win Tin Journal: J Pediatr Date: 2009-11-18 Impact factor: 4.406
Authors: Cornelia G de Waal; Gerard J Hutten; Juliette V Kraaijenga; Frans H de Jongh; Anton H van Kaam Journal: Neonatology Date: 2018-10-23 Impact factor: 4.035
Authors: Jarinda A Poppe; Willem van Weteringen; Lotte L G Sebek; Catherijne A J Knibbe; Irwin K M Reiss; Sinno H P Simons; Robert B Flint Journal: Front Pharmacol Date: 2020-05-12 Impact factor: 5.810
Authors: Joseph Pergolizzi; Alexander Kraus; Peter Magnusson; Frank Breve; Kailyn Mitchell; Robert Raffa; Jo Ann K LeQuang; Giustino Varrassi Journal: Cureus Date: 2022-01-31
Authors: Robert B Flint; Sinno H P Simons; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Irwin K M Reiss; Rob Ter Heine; Aline G J Engbers; Birgit C P Koch; Ronald de Groot; David M Burger; Catherijne A J Knibbe; Swantje Völler Journal: Pediatr Res Date: 2020-07-22 Impact factor: 3.756